FDA Proposes Priorities For Cosmetic Ingredient Review: Mica, Probiotics, CBD
Executive Summary
Nakissa Sadrieh, director of cosmetics at FDA and the agency’s CIR liaison, floated the three potential review priorities at the CIR Expert Panel’s April 8-9 meeting in Washington. It’s the most for-cause targets proposed by the agency in recent memory, and CIR leadership noted that they pose considerable challenges.
New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
